Lucien a. Aarden

Q: What Schools Are Affiliated With Lucien a. Aarden

Lucien a. Aarden is affiliated with the following schools: University of Amsterdam, Leiden University

Lucien a. Aarden's AcademicInfluence.com Rankings

Lucien a. Aarden

Biology

#8443

World Rank

#11519

Historical Rank

Molecular Biology

#1073

World Rank

#1098

Historical Rank

Neuroscience

#1170

World Rank

#1212

Historical Rank

Biochemistry

#1224

World Rank

#1343

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Lucien a. Aarden Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Lucien a. Aarden's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Oncogene-Induced Senescence Relayed by an Interleukin-Dependent Inflammatory Network (2008) (1695)
Production of hybridoma growth factor by human monocytes (1987) (1162)
Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange (2007) (854)
Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. (1989) (838)
Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production (1995) (766)
Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. (2011) (699)
Increased plasma levels of interleukin-6 in sepsis [see comments] (1989) (661)
Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis (2007) (555)
IMMUNOLOGY OF DNA. III. CRITHIDIA LUCILIAE, A SIMPLE SUBSTRATE FOR THE DETERMINATION OF ANTI‐dsDNA WITH THE IMMUNOFLUORESCENCE TECHNIQUE * (1975) (544)
Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways (1990) (529)
Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. (2006) (495)
Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. (1990) (486)
Increased plasma levels of interleukin-6 in sepsis. (1989) (475)
SERUM LEVELS OF INTERLEUKIN-6 AND ACUTE PHASE RESPONSES (1987) (466)
Functional discrimination between interleukin 6 and interleukin 1 (1988) (458)
Interleukin 6 is involved in interleukin 1‐induced activities (1988) (429)
Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: a possible role of interleukin-6 in osteoclastogenesis. (1989) (390)
On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2. (1992) (362)
Regulation of bioactive IL-12 production in lipopolysaccharide-stimulated human monocytes is determined by the expression of the p35 subunit. (1996) (335)
FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. (2002) (328)
Interleukin-8 in sepsis: relation to shock and inflammatory mediators (1992) (319)
Role of cytokines in sepsis. (1997) (316)
Endotoxin, tumor necrosis factor-α and interleukin 1 induce interleukin 6 production in vivo (1989) (293)
Anti-dsDNA and complement profiles as prognostic guides in systemic lupus erythematosus. (1979) (272)
The effect of interleukin-1, interleukin-6 and its interrelationship on the synthesis of serum amyloid A and C-reactive protein in primary cultures of adult human hepatocytes. (1988) (268)
Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. (2011) (266)
Interleukin 6 (IL-6) in serum and urine of renal transplant recipients. (1988) (265)
Sensitive ELISA for interleukin-6. Detection of IL-6 in biological fluids: synovial fluids and sera. (1991) (257)
Elevated nucleosome levels in systemic inflammation and sepsis* (2003) (244)
Histamine inhibits the production of interleukin-12 through interaction with H2 receptors. (1998) (233)
Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study (2009) (232)
Molecular cloning and expression of hybridoma growth factor in Escherichia coli. (1987) (231)
Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation. (1998) (221)
Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis (2004) (218)
Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis (2005) (208)
The relation among stress, adrenalin, interleukin 6 and acute phase proteins in the rat. (1990) (204)
Activation of interleukin-2 gene transcription via the T-cell surface molecule CD28 is mediated through an NF-kB-like response element. (1991) (201)
Regulatory properties of LFA-1 α and β chains in human T-lymphocyte activation (1988) (201)
Dealing with immunogenicity of biologicals: assessment and clinical relevance (2009) (196)
Reduced production of IL-12 and IL-12-dependent IFN-gamma release in patients with allergic asthma. (1997) (194)
The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept (2010) (194)
Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis (2006) (192)
Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. (2008) (191)
Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation (2012) (190)
A novel method for the detection of antibodies to adalimumab in the presence of drug reveals "hidden" immunogenicity in rheumatoid arthritis patients. (2010) (179)
Key findings towards optimising adalimumab treatment: the concentration-effect curve. (2015) (174)
A possible autocrine role for interleukin-6 in two lymphoma cell lines. (1989) (173)
Differential effect of drug interference in immunogenicity assays. (2011) (173)
Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266. (1991) (171)
Interleukin-6 mediates host defense responses induced by abdominal surgery. (1993) (170)
Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation (2007) (162)
Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. (2003) (160)
Activation of toll-like receptors 2 and 4 by gram-negative periodontal bacteria. (2007) (159)
Interleukin-6 induced at mucosal surfaces by gram-negative bacterial infection (1989) (147)
Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients (2011) (144)
Interleukin-6 (IL-6) in synovial fluid and serum of patients with rheumatic diseases. (1988) (142)
Chromatin-Independent Binding of Serum Amyloid P Component to Apoptotic Cells (2001) (141)
Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis (2008) (139)
The proinflammatory cytokine response to coagulation and endotoxin in whole blood. (1996) (124)
A growth-factor dependent B-cell hybridoma. (1986) (123)
Interleukin-6 and its relation to the humoral immune response and clinical parameters in burned patients. (1991) (123)
Structure-function analysis of human IL-6. Epitope mapping of neutralizing monoclonal antibodies with amino- and carboxyl-terminal deletion mutants. (1990) (121)
Interleukin (IL)‐4 production by human T cells: differential regulation of IL‐4 vs. IL‐2 production (1992) (115)
Prognostic value of anti-dsDNA in SLE. (1982) (114)
Time between onset of apoptosis and release of nucleosomes from apoptotic cells: putative implications for systemic lupus erythematosus (2003) (107)
Interleukin‐6 does not stimulate bone resorption in neonatal mouse calvariae (1991) (104)
Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation (2009) (102)
Development of a human interleukin-6 receptor antagonist. (1994) (99)
The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region (2014) (99)
Interleukin-6 synergizes with M-CSF in the formation of macrophage colonies from purified human marrow progenitor cells. (1989) (95)
Release of interleukin-12 in experimental Escherichia coli septic shock in baboons: relation to plasma levels of interleukin-10 and interferon-gamma. (1996) (95)
Modulation of IL-6 production and IL-1 activity by keratinocyte-fibroblast interaction. (1993) (94)
A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies (2013) (94)
Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis (2009) (93)
The first international standard for antibodies to double stranded DNA. (1988) (92)
Effects on leukocytes after injection of tumor necrosis factor into healthy humans (1992) (90)
Antibodies to constant domains of therapeutic monoclonal antibodies: anti-hinge antibodies in immunogenicity testing. (2012) (90)
Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation (2013) (90)
Induction of T cell proliferation with anti‐CD3 switch‐variant monoclonal antibodies: effects of heavy chain isotype in monocyte‐dependent systems (1987) (88)
Complement Activation by Apoptotic Cells Occurs Predominantly via IgM and is Limited to Late Apoptotic (Secondary Necrotic) Cells (2004) (87)
Analysis of human IL-6 mutants expressed in Escherichia coli. Biologic activities are not affected by deletion of amino acids 1-28. (1989) (86)
Avidity of antibodies to dsDNA: comparison of IFT on Crithidia luciliae, Farr assay, and PEG assay. (1982) (81)
IL-6 is an intermediate in IL-1-induced thymocyte proliferation. (1989) (81)
Functional studies with anti-CD3 heavy chain isotype switch-variant monoclonal antibodies. Accessory cell-independent induction of interleukin 2 responsiveness in T cells by epsilon-anti-CD3. (1987) (80)
Tumor necrosis factor (TNF) inhibits interleukin (IL)-1 and/or IL-6 stimulated synthesis of C-reactive protein (CRP) and serum amyloid A (SAA) in primary cultures of human hepatocytes. (1991) (79)
Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study (2010) (79)
Comparison of the effects of recombinant interleukin 6 and recombinant interleukin 1 on nonspecific resistance to infection (1989) (78)
Interleukin-6 release and the acute-phase reaction in patients with acute myocardial infarction: a pilot study. (1992) (75)
Immunology of DNA. IV. Quantitative aspects of the Farr assay. (1976) (75)
Effects on leukocytes after injection of tumor necrosis factor into healthy humans. (1992) (75)
Interleukin-6 and interleukin-1 production in acute leukemia with monocytoid differentiation. (1989) (75)
High IL‐13 production by human neonatal T cells: neonate immune system regulator? (2001) (73)
Immobilized anti-CD3 monoclonal antibodies induce accessory cell-independent lymphokine production, proliferation and helper activity in human T lymphocytes. (1989) (71)
Sensitive Measurement of Thrombopoietin by a Monoclonal Antibody Based Sandwich Enzyme-linked Immunosorbent Assay (1997) (71)
Mannan-binding lectin (MBL)-mediated opsonization is enhanced by the alternative pathway amplification loop. (2006) (71)
Immunology of DNA. I. The influence of reaction conditions on the Farr assay as used for the detection of anti-ds DNA. (1976) (69)
Development and validation of an enzyme-linked immunosorbent assay for the quantification of trastuzumab in human serum and plasma. (2009) (69)
Pentoxifylline attenuates neutrophil activation in experimental endotoxemia in chimpanzees. (1993) (69)
Human IL-13 production is negatively influenced by CD3 engagement. Enhancement of IL-13 production by cyclosporin A. (1996) (68)
Clusterin: a protective mediator for ischemic cardiomyocytes? (2005) (67)
IgG4 Production Against Adalimumab During Long Term Treatment of RA Patients (2012) (66)
Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop. (1996) (63)
Activation of factor VII-activating protease in human inflammation: a sensor for cell death (2011) (63)
Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody. (2011) (62)
Effects of smoking on the ex vivo cytokine production in periodontitis. (2009) (62)
Detection of antibodies to DNA by radioimmunoassay and immunofluorescence. (1975) (61)
Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation (2006) (60)
Characterization of IgG FcR-mediated proliferation of human T cells induced by mouse and human anti-CD3 monoclonal antibodies. Identification of a functional polymorphism to human IgG2 anti-CD3. (1992) (59)
Endotoxin and Tumor Necrosis Factor-α-Induced Interleukin-8 Release in Humans (1993) (58)
Endotoxin, tumor necrosis factor-alpha and interleukin 1 induce interleukin 6 production in vivo. (1989) (58)
Functional Analysis of the Anti-adalimumab Response Using Patient-derived Monoclonal Antibodies♦ (2014) (57)
The use of polyethylene glycol precipitation to detect low-avidity anti-DNA antibodies in systemic lupus erythematosus. (1980) (57)
Nucleosome‐releasing factor: a new role for factor VII‐activating protease (FSAP) (2008) (56)
Potentiation of Toll-like receptor-induced cytokine production by (1→3)-β-D-glucans: implications for the monocyte activation test (2007) (55)
Development of human Th1 and Th2 cytokine responses: The cytokine production profile of T cells is dictated by the primary in vitro stimulus (1993) (55)
Interleukin-4 inhibits both paracrine and autocrine tumor necrosis factor-alpha-induced proliferation of B chronic lymphocytic leukemia cells. (1992) (52)
Bivalent Llama Single-Domain Antibody Fragments against Tumor Necrosis Factor Have Picomolar Potencies due to Intramolecular Interactions (2017) (51)
Intravenous clusterin administration reduces myocardial infarct size in rats (2010) (51)
Functional polymorphisms of Fc receptors in human monocyte-mediated cytotoxicity towards erythrocytes induced by murine isotype switch variants. (1989) (50)
Effects of monocytic products, recombinant interleukin-1, and recombinant interleukin-6 on glycosylation of alpha 1-acid glycoprotein: studies with primary human hepatocyte cultures and rats. (1989) (50)
Monokine production by human T cells; IL-1 alpha production restricted to memory T cells. (1991) (50)
Tumor necrosis factor (TNF) inhibits interleukin (IL)-1 and/or IL-6 stimulated synthesis of C-reactive protein (CRP) and serum amyloid A (SAA) in primary cultures of human hepatocytes (1991) (49)
Development of an interleukin (IL) 6 receptor antagonist that inhibits IL-6-dependent growth of human myeloma cells (1994) (49)
T cell triggering by lectins I. Requirements for interleukin 2 production;er lectin concentration determines the accessory cell dependency (1985) (48)
Murine monoclonal isotype switch variants. Detection with rat monoclonal antibodies in ELISA and isolation by sequential sublining. (1988) (48)
A plasma nucleosome releasing factor (NRF) with serine protease activity is instrumental in removal of nucleosomes from secondary necrotic cells (2007) (46)
Cytokine production in whole blood cell cultures of patients with rheumatoid arthritis (1997) (45)
Mapping of Epitopes on Human Tissue-Type Plasminogen Activator with Recombinant Deletion Mutant Proteins (1987) (45)
Dissociation of DNA/anti-DNA complexes at high pH. (1980) (44)
Regulation of IL‐12 Production by Human Monocytes and the Influence of Prostaglandin E2 (1996) (44)
Cytokine production (IL-6 and TNF alpha) in whole blood cell cultures of patients with systemic lupus erythematosus. (1996) (44)
Do elevated levels of serum-soluble fas contribute to the persistence of activated lymphocytes in systemic lupus erythematosus? (1998) (43)
Soluble Fas levels in sera of bone marrow transplantation recipients are increased during acute graft-versus-host disease but not during infections. (1998) (43)
Induction of immunoglobulin synthesis by interleukin 2 is T4+/T8− cell dependent. A role for interleukin 2 in the pokeweed mitogen‐driven system (1985) (41)
Cooperation of Factor VII–Activating Protease and Serum DNase I in the Release of Nucleosomes From Necrotic Cells (2014) (41)
High levels of human anti-human antibodies to adalimumab in a patient not responding to adalimumab treatment (2006) (41)
4 – Measurements of Antibodies Specific for DNA (1981) (40)
Effect of IL-4 and IL-6 on the proliferation and differentiation of B-chronic lymphocytic leukemia cells. (1993) (39)
Epstein‐Barr virus‐dependent lymphoproliferative disease: critical role of IL‐6 (2000) (38)
Detection of anti-dsDNA as diagnostic tool. (1981) (38)
Differential induction of interleukin-6 production by monocytes, endothelial cells and smooth muscle cells. (1991) (38)
Evidence for a role of CD28RE as a response element for distinct mitogenic T cell activation signals (1992) (38)
Studies in healthy volunteers and patients with rheumatoid arthritis (2003) (36)
T cell receptor/CD3 and CD28 use distinct intracellular signaling pathways (1991) (35)
Profiles of the acute‐phase reactants C‐reactive protein and ferritin related to the disease course of patients with systemic lupus erythematosus (2003) (35)
Patients with systemic lupus erythematosus with high plasma levels of sFas risk relapse. (1999) (34)
Regulatory properties of LFA-1 alpha and beta chains in human T-lymphocyte activation. (1988) (34)
Mechanism of inhibition and induction of cytolytic activity in cytotoxic T lymphocytes by CD3 monoclonal antibodies. (1987) (33)
Cytokine-associated tissue injury and lethality in mice: a comparative study. (1991) (33)
Mycophenolic acid and methotrexate inhibit lymphocyte cytokine production via different mechanisms. (2002) (33)
Type 1- and type 2-like lesional skin-derived Mycobacterium leprae-responsive T cell clones are characterized by coexpression of IFN-gamma/TNF-alpha and IL-4/IL-5/IL-13, respectively. (1998) (32)
Hybridoma Growth Factor (1989) (32)
Monocyte‐dependent induction of proliferation of human peripheral T cells by recombinant interleukin 2 (1986) (31)
Mannan binding lectin in febrile adults: no correlation with microbial infection and complement activation (2003) (30)
Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies. (2010) (30)
Detection and characterization of DNA-anti-DNA complexes in a patient with systemic lupus erythematosus. (1977) (30)
High-throughput analysis of the C4 polymorphism by a combination of MLPA and isotype-specific ELISA's. (2009) (29)
Polymorphism of the Human Fcγ Receptor II (CD32): Molecular Basis and Functional Aspects (1992) (29)
A new principle for rapid immunoassay of proteins based on in situ precipitate-enhanced ellipsometry. (1999) (29)
Specificity in systemic lupus erythematosus of antibodies to double-stranded DNA measured with the polyethylene glycol precipitation assay. (1982) (29)
Cytokine induction by pyrogens: comparison of whole blood, mononuclear cells, and TLR-transfectants. (2008) (29)
Interleukin-6 (IL-6) and acute phase proteins in the disease course of patients with systemic lupus erythematosus (2004) (28)
Preferential decrease in IgG4 anti-citrullinated protein antibodies during treatment with tumour necrosis factor blocking agents in patients with rheumatoid arthritis (2008) (28)
Complement-fixing antibodies to dsDNA detected by the immunofluorescence technique on Crithidia luciliae. A critical appraisal. (1985) (28)
Inhibition of interleukin‐12 expression by α‐thrombin in human peripheral blood mononuclear cells: a potential mechanism for modulating Th1/Th2 responses (2003) (28)
Induction of T-cell proliferation by recombinant mouse and chimeric mouse/human anti-CD3 monoclonal antibodies. (1991) (28)
Release of leukemia inhibitory factor in primate sepsis. Analysis of the role of TNF-alpha. (1996) (27)
Comparison between dissociation and inhibition of association of DNA/anti-DNA complexes. (1983) (26)
On the interaction between agalactosyl IgG and Fcγ receptors (1996) (26)
Inhibition of association vs. dissociation of high-avidity DNA/anti-DNA complexes:possible involvement of secondary hydrogen bonds. (1985) (26)
Interleukin-6 production by tumor necrosis factor and lipopolysaccharide-stimulated rat renal cells. (1990) (26)
An improved incubation apparatus for Western blots used for the detection of antinuclear antibodies. (1986) (25)
Measurement of low avidity anti-dsDNA by the Crithidia luciliae test and the PEG assay. (1982) (25)
Immunology of DNA. V. Analysis of DNA/anti-DNA complexes. (1976) (25)
Blocking interleukin-6 activity with chimeric anti-IL6 monoclonal antibodies in multiple myeloma: effects on soluble IL6 receptor and soluble gp130. (1998) (25)
Label-free assessment of high-affinity antibody-antigen binding constants. Comparison of bioassay, SPR, and PEIA-ellipsometry. (2011) (24)
Functional Disparity of Distinct CD28 Response Elements toward Mitogenic Responses* (1999) (24)
Variable mannose-binding lectin expression during postoperative acute-phase response. (2006) (24)
T cell function in systemic lupus erythematosus: normal production of and responsiveness to interleukin 2. (1986) (23)
Nuclear Appearance of a Factor That Binds the CD28 Response Element within the Interleukin-2 Enhancer Correlates with Interleukin-2 Production (*) (1996) (23)
IgE production in atopic patients is not related to IL‐4 production (1994) (23)
Apolipoprotein H, a new mediator in the inflammatory changes ensuing in jeopardised human myocardium (2000) (23)
Characterisation of monoclonal antibodies to human IL-4: application in an IL-4 ELISA and differential inhibition of IL-4 bioactivity on B cells and T cells. (1993) (21)
The minipig as an alternative non-rodent model for immunogenicity testing using the TNFα blockers adalimumab and infliximab (2014) (21)
Endotoxin and tumor necrosis factor-alpha-induced interleukin-8 release in humans. (1993) (20)
Tissue factor pathway inhibitor is an inhibitor of factor VII‐activating protease (2012) (20)
Histone and DNA detection in swollen spermatozoa and somatic cells, by immunofluorescence. (1976) (20)
Cytokines and intracellular signals involved in the regulation of B-CLL proliferation. (1993) (19)
Serum interleukin-6 levels and adverse reactions to diethylcarbamazine in lymphatic filariasis. (1992) (19)
Interleukin-8 (IL-8) in synovial fluid of rheumatoid and nonrheumatoid joint effusions (1993) (19)
An improved monocyte activation test using cryopreserved pooled human mononuclear cells (2015) (18)
Induction of IgM production by pokeweed mitogen and interleukin-2: different responses by human peripheral blood cells and tonsil cells. (1986) (18)
Two Inhibitors of DNA‐Synthesis Lead to Inhibition of Cytokine Production via a Different Mechanism (2004) (17)
FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and prote (2002) (17)
T cell triggering by lectins II. Stimuly for induction of interleukin 2 responsiveness and interleukin 2 production differ only in quantitative aspects (1985) (16)
Two monoclonal anti‐CD3 antibodies can induce different events in human T lymphocyte activation (1987) (16)
Soluble CD95 concentrations are increased in patients with severe systemic lupus erythematosus, but not in their first degree relatives (2001) (16)
Influence of pH on the detection of low- and high-avidity anti-dsDNA. (1982) (16)
On the Interaction of IgG Subclasses with the Low Affinity FcyRlla ( CD 32 ) on Human Monocytes , Neutrophils , and Platelets Analysis of a Functional Polymorphism to Human IgG 2 (2013) (15)
Co‐Stimulation of T cells via CD28 inhibits human IgE production; reversal by Pertussis toxin (1995) (15)
FSAP, a new player in inflammation? (2012) (14)
Studies on the monocyte dependence of T-cell proliferation induced by monoclonal antibodies directed against regions I and II of the CD2 antigen. (1989) (13)
Differentiation of purified malignant B cells induced by PMA or by activated normal T cells. (1993) (13)
Immunology of DNA. VI. The effect of mercaptans on IgG and IgM anti-dsDNA. (1977) (13)
Interleukin 2 induces T cell‐dependent IgM production in human B cells (1985) (13)
Polymorphism of the human Fc gamma receptor II (CD32): molecular basis and functional aspects. (1992) (12)
Changes of ferritin and CRP levels in melanoma patients treated with adjuvant interferon-&agr; (EORTC 18 952) and prognostic value on treatment outcome (2011) (12)
Measurement of interleukin-6 production by monocytes for in vitro safety testing of hemoglobin solutions. (1994) (12)
PGE2 and the immune response (1995) (10)
Interleukin-6 enhances human Ig production, but not as a terminal differentiation factor for B lymphocytes. (1990) (10)
Azathioprine in the treatment of systemic lupus erythematosus. A three-year prospective study (1984) (10)
Human transferrin allows efficient IgE production by anti‐CD3‐stimulated human lymphocytes at low cell densities (1991) (9)
Genetic risk factors for autoimmune diseases. (1999) (9)
Leucine‐58 in the putative 5th helical region of human interleukin (IL)‐6 is important for activation of the IL‐6 signal transducer, gp130 (1995) (9)
State and diagnostic value of plasma tissue factor in early‐hospitalised patients with chest pain (2005) (8)
The action of interleukin 6 on lymphoid populations. (2007) (8)
Monoclonal anti-peroxidase isotype switch variants. Applications in studies of protein A binding and characterization of rat monoclonal antibodies. (1987) (7)
Both naive and memory T cells can provide help for human IgE production, but with different cytokine requirements. (1992) (7)
FSAP‐mediated nucleosome release from late apoptotic cells is inhibited by autoantibodies present in SLE (2016) (7)
Development of Human IL‐6 Receptor Antagonists (1995) (7)
Development of anti-drug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up (2013) (7)
A novel interleukin in serum and urine of renal transplant recipients (1988) (7)
Induction of proliferation of B prolymphocytic leukemia cells by phorbol ester and native or recombinant interferon-gamma (1987) (7)
Polymorphism in the IL-13 Promoter (1999) (6)
On the interaction between agalactosyl IgG and Fc gamma receptors. (1996) (6)
Anti‐CD3 antibodies induce T helper function for human B cell differentiation in vitro by an interleukin 2‐independent pathway (1988) (6)
Human chromosome 21 determines growth factor dependence in human/mouse B-cell hybridomas. (1998) (6)
4-Hydroxy-oxyphenbutazone is a potent inhibitor of cytokine production. (2005) (5)
Response to: 'The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region’ by Rinaudo-Gaujous et al (2015) (5)
Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus: comment on the article by Esdaile et al. (1996) (5)
Identification of residues in the putative 5th helical region of human interleukin‐6, important for activation of the IL‐6 signal transducer, gp130 (1996) (5)
Purification of bovine thyroid-stimulating hormone by a monoclonal antibody. (1988) (5)
High-affinity antibodies in a new immunoassay for plasma tissue factor: reduction in apparent intra-individual variation (2005) (4)
Effects of monocytic products, recombinant interleukin-1, and recombinant interleukin-6 on glycosylation of α1acid glycoprotein (1989) (4)
PGE2 and the immune response. A central role for prostaglandin E2 in downregulating the inflammatory immune response. (1995) (4)
Differential induction of interleukin-6 production in monocytes, endothelial cells and smooth muscle cells. (1991) (4)
Regulation of malignant B-cell proliferation by direct binding of anti-HLA class-II antibodies. (1988) (4)
Interleukin-6: its role in the cytokine network (1992) (4)
Regulation of IL-2 gene transcription via the T-cell surface molecule CD28 (1991) (3)
TNF‐α induces spreading of B‐CLL via the CD11C/CD18 molecule (1993) (3)
Biological Assay of Interleukins (1990) (3)
Analysis of T cell‐replacing factor‐like activity: potent induction of T helper activity for human B cells by residual concanavalin A and interleukin 2 (1987) (3)
Preferential decrease in IgG 4 anti-citrullinated protein antibodies during treatment with tumour necrosis factor blocking agents in patients with rheumatoid arthritis (2009) (3)
Cooperation of Factor VII-activating protease and serum Deoxyribonuclease I in release of nucleosomes from necrotic cells (2016) (3)
The Release of Interleukin‐12 in Escherichia co/i‐Induced Lethal and Sublethal Primate Sepsis (1996) (3)
Analysis of T-cell-derived factors with the use of B-prolymphocytic leukemia cells. (1988) (3)
Induction of proliferation of B prolymphocytic leukemia cells by phorbol ester and native or recombinant interferon-gamma. (1987) (2)
Eular workshop on Rheumatology Research (1982) (2)
IgG4 Production Against Adalimumab During Long Term Treatment of RA Patients (2012) (2)
Isotype-specific cross-linking of select human Fc gamma R isoforms triggers release of IL-6. (1993) (2)
Intravenous clusterin administration reduces myocardial infarct size in rats: CLUSTERIN ADMINISTRATION REDUCES INFARCT SIZE (2010) (2)
9341 Changes of ferritin and CRP levels in melanoma patients treated with adjuvant interferon a (EORTC 18952) have no prognostic value on treatment outcome (2009) (2)
Two Inhibitors of DNA-Synthesis Lead to Inhibition of Cytokine Production via a Different Mechanism (2005) (1)
Modulation of chronic excessive interleukin-6 production in multiple myeloma does not affect thyroid hormone concentrations. (1997) (1)
TNF-alpha induces spreading of B-CLL via the CD11c/CD18 molecule. (1993) (1)
[The formation of infliximab and anti-infliximab immune complexes as an explanation for non-responding to infliximab treatment of rheumatoid arthritis: observational study in 4 patients]. (2008) (1)
Histamine, through interaction with H2 receptors, and PGE-2 inhibit the production of human bioactive interleukin-12 (1997) (1)
FRI0188 The impact of immunogenicity on drug safety profile (2013) (1)
An IL-6 receptor antagonist for IL-6 activity on human myeloma cells (1994) (1)
Apoptosis In Sepsis And Multiple Organ Dysfunction Syndrome (2004) (1)
Mycophenolicc acid and methotrexate inhibitt lymphocyte cytokine production via differentt mechanisms (2007) (1)
AB0055 Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralization (2013) (1)
Last Minute Subjects (1975) (1)
4 The clinical relevance of immunogenicity in a long-term follow-up cohort of adalimumab treated rheumatoid arthritis patients (2011) (0)
Short-term pioglitazone treatment does not affect cytokine production of monocytes in contrast with the natural PPAR-γ ligand prostaglandin J 2 (2005) (0)
Triggering of Fas can prevent apoptosis (1997) (0)
Studiess in healthy volunteers and patients with rheumatoid arthritis (2007) (0)
anti-infliximab formation ankylosing spondylitis is correlated with Decreased clinical response to infliximab in (2007) (0)
The role of cytokines in allergic asthma (1999) (0)
Circulating complexes between C1q and anti-C1q in systemic lupus erythematosus (2008) (0)
P65The lectin pathway is inhibited by an anti-coagulant protease inhibitor acting on MASP-2 (2011) (0)
IX Eular Workshop for Rheumatology Research (1989) (0)
Structure-function analysis oh human interleukin-6. (1992) (0)
patients with rheumatoid arthritis Cytokine production in whole blood cell cultures of (2006) (0)
but not in their first degree relatives patients with severe systemic lupus erythematosus, Soluble CD95 concentrations are increased in (2006) (0)
Fluctuating levels of serum soluble Fas in relation to disease activity and lymphocyte activation in systemic lupus erythematosus. (1997) (0)
SAT0187 Tocilizumab Standard Dose is an Overtreatment with Regard to Systemic IL-6 Receptor Blockade in Rheumatoid Arthritis (2015) (0)
Portal Histamine inhibits the production of interleukin-12 through interaction with H 2 receptors (1998) (0)
Genetic regulation of interleukin-13 production (2002) (0)
Pharmacological modulation of the acute phase response in experimental colitis (1994) (0)
cells factor-alpha-induced proliferation of B chronic lymphocytic leukemia Interleukin-4 inhibits both paracrine and autocrine tumor necrosis (2011) (0)
FRI0147 IgG4 antibody response upon long term treatment with adalimumab (2013) (0)
Symposium 9: Analytical problems and biological significance of cytokines in body fluids (1990) (0)
Measurement of interleukin 6 (1990) (0)
Activation Vascular Cytokine Response to Coagulation Potential Mechanisms for a Proinflammatory Creasey and Lucien (1998) (0)
COMMENT ON: LABORATORY TESTS AS PREDICTORS OF DISEASE EXACERBATION IN SYSTEMIC LUPUS ERYTHEMATOSUS (1996) (0)
THROMBIN STIMULATES A PROINFLAMMATORY CYTOKINE RESPONSE BY MONOCYTES AND ENDOTHELIAL CELLS: 160 (1997) (0)
Chapterr 5 AA differentia l effec t of MPA on monokin e production , , evidenc e for inductio n os IL-11 p productio n (2007) (0)
CHAPTER 4 INTERLEUKIN-6 , FEVER AND ACUTE PHASE RESPONSES IN PATIENTS WITH BURNS (2001) (0)
Regulation de la synthese et de la liberation de la cytokine (1996) (0)
Correlation between genetic profile, serum levels and functionality of the polymorphic complement protein C4 (2007) (0)
Amyloid P Component to Apoptotic Cells Chromatin-Independent Binding of Serum (2001) (0)
A1.79 A preliminary algorithm introducing immunogenicity assessment in the management of RA patients receiving biotechnological therapies (2014) (0)
UvA-DARE ( Digital Academic Repository ) Inhibition of cytokine production by methotrexate . Studies in healthy volunteers and patients with rheumatoid arthritis (2017) (0)
10. Cytokine production by human osteoblast-like cells in vitro (1989) (0)
From Poisson Distribution to Interleukins (2005) (0)
UvA-DARE ( Digital Academic Repository ) The role of mannose-binding lectin in vitro and in vivo (2008) (0)
Humann intravenous immunoglobulin preparations degranulate humann neutrophils in vitro (2007) (0)
Lesional skin derived Type 1- and Type 2-like Mycobacterium leprae responsive T cells are characterized by co-production of IFN-γ and TNF-α, versus IL-4, IL-5 and IL-13 (1997) (0)
The coagulant and inflammatory properties of phospholipid microparticles generated in vivo (2001) (0)
Technical aspects of ANA determination. (1985) (0)
with rheumatoid arthritis clinical response to infliximab treatment in patients levels, pretreatment C reactive protein levels, and Relationship between serum trough infliximab (2006) (0)
UvA-DARE ( Digital Academic Repository ) Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis (2009) (0)
The IgG4 subclass of anti-citrullinated protein antibodies preferentially decreases during treatment with TNF blocking agents in patients with rheumatoid arthritis (2011) (0)
Type 1- and Type 2-Like Lesional Skin-Derived Mycobacterium leprae-Responsive T Cell Clones Are Characterized by Coexpression of IFN-γ/TNF-α and IL-4/IL-5/IL-13, Respectively (1998) (0)
Protease-activated receptor-1 and angiogenesis: downregulation of TH1-type cytokines by alpha-thrombin (2003) (0)
Regulation of IL-2 gene expression through CD28 is dependent on cooperativity between cis-acting promoter sequences (1997) (0)
PHAGOCYTOSIS OF DNA-ANTI-DNA COMPLEXES BY HUMAN PMN VIA Fc AND C3 RECEPTOR (1976) (0)
CD95 monoclonal antibodies can induce cell death without external multimerization and modulate Fas induced cell death (1997) (0)
Chapterr 7 Inn vitr o T-cell activatio n is decrease d two hour ss after MTX intak e and does not predic tt clinica l response . (2007) (0)
The Role of T and B Cells in Transfusion Related Immune Reac-Tions: Cytokines and the Removal of Apoptotic Material (1999) (0)
UvA-DARE ( Digital Academic Repository ) A new principle for rapid immunoassay of proteins based on in situ precipate-enhanced ellipsometry (1999) (0)
P29. Human recombinant interleukin-6 (IL-6) and bone resorption (1989) (0)
Factor VII-Activating Protease Is a Regulator of Histone Cytotoxicity (2015) (0)
IL-13-producing cells after in vitro allergen stimulation in atopic individuals: Effect of pollen season and allergen immunotherapy (1997) (0)
FSAP and DNase I release nucleosomes from necrotic cells (2014) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Lucien a. Aarden?

Lucien a. Aarden is affiliated with the following schools:

Lucien a. Aarden's Academic­Influence.com Rankings

Why Is Lucien a. Aarden Influential?

Lucien a. Aarden's Published Works

Published Works

What Schools Are Affiliated With Lucien a. Aarden?

Lucien a. Aarden's AcademicInfluence.com Rankings